Donidalorsen
Based on 1 Customer Validation
Donidalorsen (ISIS-721744; IONIS-PKK-LRX free acid) is an antisense oligonucleotide targeting prekallikrein (PKK). Donidalorsen inhibits kallikrein activity and reduces the production of Bradykinin (HY-P0206) by specifically binding to and degrading PKK mRNA in the liver. Donidalorsen can be used in the research of hereditary angioedema.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 98.39%
- No. CAS: 2304692-48-4
- Fòrmula: C296H435N83O151P20S15
- Peso molecular:8672.64
-
Almacenamiento:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Actividad biológica
Donidalorsen binds selectively to hepatic prekallikrein mRNA, mediates its degradation via ribonuclease H1, reduces hepatic prekallikrein production, reduces plasma prekallikrein concentrations, reduces plasma D-dimer concentrations, inhibits prekallikrein protein production, and reduces hereditary angioedema attack frequency[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 2304692-48-4
-
Appearance Solid
-
Peso molecular 8672.64
-
Fòrmula C296H435N83O151P20S15
-
Color White to off-white
-
SMILES
[Donidalorsen]
-
Synonyms
ISIS-721744 free acid; IONIS-PKK-LRX free acid
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Pureza y Documentación
-
Ficha de datos (265 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instrucciones de manejo (2242 KB)
Referencias
[1]. Petersen RS, et al. A phase 2 open-label extension study of prekallikrein inhibition with donidalorsen for hereditary angioedema. Allergy. 2024;79(3):724-734. [Content Brief]
[2]. Diep JK, et al. Population Pharmacokinetic/Pharmacodynamic Modeling of Donidalorsen, an Antisense Oligonucleotide in Development for Prophylaxis of Hereditary Angioedema. CPT Pharmacometrics Syst Pharmacol. 2026;15(2):e70206. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)